- Home
- PRGS vs NNNN Comparison
PRGS vs NNNN Comparison
Compare PRGS & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRGS | NNNN |
|---|---|---|
| Founded | 1981 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | PRGS | NNNN |
|---|---|---|
| Price | $34.52 | $21.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $66.33 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 38.7K |
| Earning Date | 04-21-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.79 | N/A |
| EPS | ★ 1.66 | N/A |
| Revenue | ★ $397,572,000.00 | N/A |
| Revenue This Year | $3.60 | N/A |
| Revenue Next Year | $1.28 | N/A |
| P/E Ratio | ★ $21.49 | $446.57 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $34.57 | $5.91 |
| 52 Week High | $65.50 | $55.65 |
Technical Indicators
Market Signals| Indicator | PRGS | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 34.57 | 40.23 |
| Support Level | N/A | $19.25 |
| Resistance Level | $44.09 | $31.44 |
| Average True Range (ATR) | 1.93 | 2.40 |
| MACD | -0.42 | -0.19 |
| Stochastic Oscillator | 7.72 | 0.33 |
Price Performance
Historical ComparisonAbout PRGS Progress Software Corporation (DE)
Progress Software Corp provides software operate in one operating segment: software products for the development, deployment, and management of responsible, AI-powered applications and digital experiences. The following are products: Chef, Corticon, Data Direct, Developer Tools, Flowmon, Kemp LoadMaster, MarkLogic, MOVEit, OpenEdge, Semaphore, ShareFile, Sitefinity, WhatsUp Gold. Geographical regions include the United States, Canada, EMEA, Latin America, and Asia Pacific.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.